Abstract
Introduction/Background
Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma
patients, providing they have stage II disease with an intermediate risk of recurrence,
or stage III but they are above 70’s or they have comorbidities. We wanted to examine
whether the number of chemotherapy cycles and the relative dose intensity (RDI) of
capecitabine monotherapy in the adjuvant setting are affecting disease recurrence.
Patients and Methods
We included patients with completely resected stage II and III colon and upper rectum
cancer who received adjuvant capecitabine monotherapy, from 2003 until May 2020. Patients
with early relapse, i.e. during chemotherapy or within 6 months after the completion
of adjuvant chemotherapy, and those with rectal cancer who received radiotherapy were
excluded. Patients were divided into 3 groups based on the number of chemotherapy
cycles received and the RDI. Group A included patients with ≤4 cycles of chemotherapy,
group B patients with >4 cycles of chemotherapy and RDI ≤80%, and group C patients
with >4 cycles of chemotherapy and RDI >80%. Study’s endpoint, was recurrence free
survival (RFS).
Results
Two hundred twenty six patients with stage II and III disease (164 and 62 respectively)
were included. Sixteen, 166 and 44 were included in groups A, B and C respectively.
After a median follow-up of 41 months, 21 patients (9,3%) had relapsed. Patients belonging
to group C were found to have a trend for lower relapse rate compared to patients
belonging to group A or group B.
Conclusion
Number of adjuvant capecitabine cycles and RDI might play a role in RFS in patients
with stage II and III colon and upper rectum adenocarcinoma.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
- Adjuvant chemotherapy in elderly colorectal cancer patients.Cancers. 2020; 12: 2289https://doi.org/10.3390/cancers12082289
- Localized colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2020; 31: 1291-1305https://doi.org/10.1016/j.annonc.2020.06.022
- Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.N Engl J Med. 2004; 350: 2343-2351https://doi.org/10.1056/NEJMoa032709
- The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: a systematic review and meta-analysis.Ther Adv Med Oncol. 2021; 131758835920986520https://doi.org/10.1177/1758835920986520
- Capecitabine as adjuvant treatment for stage III colon cancer.N Engl J Med. 2005; 352: 2696-2704https://doi.org/10.1056/NEJMoa043116
- Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer.Ann Oncol. 2012; 23: 911-918https://doi.org/10.1093/annonc/mdr329
- AJCC Cancer Staging Manual.(eds)8th ed. Springer, New York2017
- Relative dose intensity of systemic chemotherapy in an outpatient cancer center.Acta Medica Academica. 2010; 39: 144-149
- The calculation of actual or received dose intensity: a comparison of published methods.J Clin Oncol. 1991; 9: 2042-2051https://doi.org/10.1200/JCO.1991.9.11.2042
- Duration of adjuvant chemotherapy for stage III colon cancer.N Engl J Med. 2018; 378: 1177-1188https://doi.org/10.1056/NEJMoa1713709
- SAS® 9.4 Statements: Reference. Cary.SAS Institute Inc, NC2013
- Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.J Natl Cancer Inst. 2007; 99: 998-1003https://doi.org/10.1093/jnci/djm024
- Reintroduction of irinotecan and oxaliplatin as a combination (IROX) in heavily pretreated colorectal cancer patients. A single center experience.Forum Clin Oncol. 2013; 4: 13-18
- Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.Int J Cancer. 2017; 140: 224-233https://doi.org/10.1002/ijc.30423
- Association of survival outcomes with dose intensity of adjuvant therapy (AT) with capecitabine for colorectal cancer (CRC).J Clin Oncol. 2010; 28: 3624https://doi.org/10.1200/jco.2010.28.15_suppl.3624
- Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.BMC Cancer. 2015; 15: 62https://doi.org/10.1186/s12885-015-1038-y
- Association between adjuvant chemotherapy duration and survival among patients with stage II and III colon cancer: a systematic review and meta-analysis.JAMA Netw Open. 2019; 2e194154https://doi.org/10.1001/jamanetworkopen.2019.4154
- The influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis.Curr Oncol. 2021; 28: 4031-4041https://doi.org/10.3390/curroncol28050342
- Impact of dose reductions, delays between chemotherapy cycles, and/or shorter courses of adjuvant chemotherapy in stage II and III colorectal cancer patients: a single-center retrospective study.J Gastrointest Cancer. 2015; 46: 343-349https://doi.org/10.1007/s12029-015-9746-8
- Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.Ann Oncol. 2020; 31: 921-929https://doi.org/10.1016/j.annonc.2020.03.310
- Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).Ann Oncol. 2022; 33: 628-637https://doi.org/10.1016/j.annonc.2022.03.002
- Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.N Engl J Med. 2022; 386: 2261-2272https://doi.org/10.1056/NEJMoa2200075
Article info
Publication history
Published online: March 03, 2023
Accepted:
February 28,
2023
Received in revised form:
February 26,
2023
Received:
September 9,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
